American Society of Hirudotherapy

Bivalirudin versus heparin anticoagulation in patients receiving extracorporeal membrane oxygenation

Huang D, Guan Q, Qin J, Shan R, Wu J, Zhang C (2022) · Perfusion · n=1232

RCT evidence detailTrial reference
GRADE LowCohort / case seriesBivalirudin: drug studies
Sample size of this trial compared with other Bivalirudin: drug studies trialsMehran R 20093602Huang D 20221232Fuchs J 1995410Valdes CA 2023313Hamzah M 2023225Wang ZD 2022210Iaprintsev V 202575Zhang Y 202442Trigonis R 202142McMichael A 202430
This trial (highlighted) by sample size alongside other indexed Bivalirudin: drug studies trials. Larger trials generally carry more statistical weight.

Study Profile

Design
systematic review and meta-analysis of 12 retrospective cohort studies through April 2022 (PubMed, Embase, Cochrane Library)
Sample size (n)
1232
Intervention
Bivalirudin anticoagulation for ECMO (n=497 across pooled cohorts)
Comparator
Unfractionated heparin anticoagulation (n=735)
Primary endpoint
In-hospital mortality (short-term death)
Primary result
No significant difference in mortality (RR 0.95, 95% CI 0.79-1.13, p=0.546) or thrombotic events (RR 0.78, 95% CI 0.45-1.35); bivalirudin significantly reduced bleeding events (RR 0.48, 95% CI 0.25-0.95, p=0.035)
Follow-up duration
Hospital discharge
PMID
35616224

Key Findings

  • Largest contemporary pooled dataset (n=1,232) on ECMO anticoagulation choice
  • Equivalent mortality between bivalirudin and heparin
  • Equivalent thrombotic event rates
  • Bivalirudin associated with reduced bleeding complications (52% relative reduction)
  • Highlights need for prospective RCTs

Limitations

  • All included studies were retrospective observational
  • Significant clinical heterogeneity across centers
  • Publication bias likely
  • Patient selection bias - sicker patients more likely to receive bivalirudin
  • Not applicable to whole-leech hirudotherapy

Clinical Implications

Huang 2022 is a foundational evidence synthesis for ECMO anticoagulation choice. For ASH, the meta-analysis demonstrates how the synthetic hirudin-derivative pathway operates under retrospective observational evidence with bleeding-reduction signal but no mortality benefit. This evidence base is structurally distinct from the device-leech K040187 US practice and serves as a reference for the broader hirudin-derived anticoagulant landscape.

Related Trials

Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial

Fuchs J, Cannon CP (1995)

Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial

Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW (2009)

Experience with pharmacologic leeching with bivalirudin for adjunct treatment of venous congestion of head and neck reconstructive flaps

Harun A, Kruer RM, Lee A, Boahene K, Byrne PJ, Richmon JD (2018)

Heparin and Bivalirudin in Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Review Article

Wang G, Qi K, Li X, Zuo S, Zhang R, Zhao Y, Sun S, Zhang J, Liu X (2024)

← Back to RCT Library

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.